Junshi Biosciences Says JS207 Dual Antibody in Phase II Trials
Junshi Biosciences (688180) said at its 2026 interim results briefing on September 14 that JS207, a PD-1/VEGF bispecific antibody, is in Phase II clinical studies. The company is exploring combinations of JS207 with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types, and plans to start Phase III clinical studies within 2026.
JS207, a PD-1/VEGF bispecific antibody, is currently in Phase II clinical studies, with combination explorations underway across multiple tumor types with chemotherapy, monoclonal antibodies, ADCs and other agents. The company plans to initiate Phase III clinical studies within 2026.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 70% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 50
- Confidence
- 70%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 40
- Confidence
- 60%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.